7. Management of metabolic dysfunction-associated steatotic liver disease (MASLD) in type 2 diabetes

被引：0
作者：
Colagiuri, Stephen [1 ]
Ceriello, Antonio [2 ]
机构：
[1] Univ Sydney, Sydney, Australia
[2] IRCCS MultiMed, Milan, Italy
来源：
DIABETES RESEARCH AND CLINICAL PRACTICE | 2025年 / 222卷
关键词：
CONTROLLED-TRIAL; PIOGLITAZONE; FIBROSIS; PLACEBO;
D O I：
10.1016/j.diabres.2025.112151
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页数：5
相关论文
共 36 条
[1]   Empagliflozin Reduces Liver Fat in Individuals With and Without Diabetes [J].
Abdelgani, Siham ;
Khattab, Ahmed ;
Adams, John ;
Baskoy, Gozde ;
Brown, Marissa ;
Clarke, Geoff ;
Larvenenko, Olga ;
DeFronzo, Ralph A. ;
Abdul-Ghani, Muhammad .
DIABETES CARE, 2024, 47 (04) :668-675
[2]   Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis [J].
Aithal, Guruprasad P. ;
Thomas, James A. ;
Kaye, Philip V. ;
Lawson, Adam ;
Ryder, Stephen D. ;
Spendlove, Ian ;
Austin, Andrew S. ;
Freeman, Jan G. ;
Morgan, Linda ;
Weeber, Jonathan .
GASTROENTEROLOGY, 2008, 135 (04) :1176-1184
[3]  
[Anonymous], 2024, Gastroenterol Hepatol (N Y), V20, P6
[4]   EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis-2021 update [J].
Berzigotti, Annalisa ;
Tsochatzis, Emmanouil ;
Boursier, Jerome ;
Castera, Laurent ;
Cazzagon, Nora ;
Friedrich-Rust, Mireen ;
Petta, Salvatore ;
Thiele, Maja .
JOURNAL OF HEPATOLOGY, 2021, 75 (03) :659-689
[5]   Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease [J].
Budd, Jeffrey ;
Cusi, Kenneth .
CURRENT DIABETES REPORTS, 2020, 20 (11)
[6]   High Prevalence of NASH and Advanced Fibrosis in Type 2 Diabetes: A Prospective Study of 330 Outpatients Undergoing Liver Biopsies for Elevated ALT, Using a Low Threshold [J].
Castera, Laurent ;
Laouenan, Cedric ;
Vallet-Pichard, Anais ;
Vidal-Trecan, Tiphaine ;
Manchon, Pauline ;
Paradis, Valerie ;
Roulot, Dominique ;
Gault, Nathalie ;
Boitard, Christian ;
Terris, Benoit ;
Bihan, Helene ;
Julla, Jean-Baptiste ;
Radu, Alina ;
Poynard, Thierry ;
Brzustowsky, Angelique ;
Larger, Etienne ;
Czernichow, Sebastien ;
Pol, Stanislas ;
Bedossa, Pierre ;
Valla, Dominique ;
Gautier, Jean-Francois .
DIABETES CARE, 2023, 46 (07) :1354-1362
[7]   Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis [J].
Cho, Elina En Li ;
Ang, Chong Zhe ;
Quek, Jingxuan ;
Fu, Clarissa Elysia ;
Lim, Lincoln Kai En ;
Heng, Zane En Qi ;
Tan, Darren Jun Hao ;
Lim, Wen Hui ;
Yong, Jie Ning ;
Zeng, Rebecca ;
Chee, Douglas ;
Nah, Benjamin ;
Lesmana, Cosmas Rinaldi Adithya ;
Bwa, Aung Hlaing ;
Win, Khin Maung ;
Faulkner, Claire ;
Aboona, Majd B. ;
Lim, Mei Chin ;
Syn, Nicholas ;
Kulkarni, Anand V. V. ;
Suzuki, Hiroyuki ;
Takahashi, Hirokazu ;
Tamaki, Nobuharu ;
Wijarnpreecha, Karn ;
Huang, Daniel Q. Q. ;
Muthiah, Mark ;
Ng, Cheng Han ;
Loomba, Rohit .
GUT, 2023, 72 (11) :2138-2148
[8]   Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus A Randomized Trial [J].
Cusi, Kenneth ;
Orsak, Beverly ;
Bril, Fernando ;
Lomonaco, Romina ;
Hecht, Joan ;
Ortiz-Lopez, Carolina ;
Tio, Fermin ;
Hardies, Jean ;
Darland, Celia ;
Musi, Nicolas ;
Webb, Amy ;
Portillo-Sanchez, Paola .
ANNALS OF INTERNAL MEDICINE, 2016, 165 (05) :305-+
[9]   Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial [J].
Gastaldelli, Amalia ;
Cusi, Kenneth ;
Fernandez Lando, Laura ;
Bray, Ross ;
Brouwers, Bram ;
Rodriguez, Angel .
LANCET DIABETES & ENDOCRINOLOGY, 2022, 10 (06) :393-406
[10]   Liver-targeting drugs and their effect on blood glucose and hepatic lipids [J].
Gastaldelli, Amalia ;
Stefan, Norbert ;
Haering, Hans-Ulrich .
DIABETOLOGIA, 2021, 64 (07) :1461-1479
1234